Please use this identifier to cite or link to this item:
https://doi.org/10.1186/s12885-018-5110-2
DC Field | Value | |
---|---|---|
dc.title | Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases | |
dc.contributor.author | Tan, Wan-Ling | |
dc.contributor.author | Ng, Quan Sing | |
dc.contributor.author | Lim, Cindy | |
dc.contributor.author | Tan, Eng Huat | |
dc.contributor.author | Toh, Chee Keong | |
dc.contributor.author | Ang, Mei-Kim | |
dc.contributor.author | Kanesvaran, Ravindran | |
dc.contributor.author | Jain, Amit | |
dc.contributor.author | Tan, Daniel SW | |
dc.contributor.author | Lim, Darren Wan-Teck | |
dc.date.accessioned | 2022-04-07T08:39:27Z | |
dc.date.available | 2022-04-07T08:39:27Z | |
dc.date.issued | 2018-12-03 | |
dc.identifier.citation | Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel SW, Lim, Darren Wan-Teck (2018-12-03). Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC CANCER 18 (1). ScholarBank@NUS Repository. https://doi.org/10.1186/s12885-018-5110-2 | |
dc.identifier.issn | 14712407 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/218617 | |
dc.description.abstract | Background: Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) non-small cell lung cancer (NSCLC). Dose dependent side effects can limit drug exposure, which may impact on extracranial and central nervous system (CNS) disease control. Methods: We performed a retrospective study of 125 patients diagnosed with advanced EGFRm+ NSCLC treated with first-line afatinib at a tertiary Asian cancer center, exploring clinicopathological factors that may influence survival outcomes. Median progression free survival (PFS) was estimated using the Kaplan-Meier method. Comparison of PFS between subgroups of patients was done using log-rank tests and Cox proportional hazards models. Results: Out of 125 patients, 62 (49.6%) started on 40 mg once daily (OD) afatinib, 61 (48.8%) on 30 mg OD and 1 (0.8%) on 20 mg OD. After median follow-up of 13.8 months from afatinib initiation, the observed response rate was 70.4% and median PFS 11.9 months (95% CI 10.3-19.3). 42 (33.6%) patients had baseline brain metastases (BM) and PFS of those who started on 40 mg OD (n = 17) vs. 30 mg OD (n = 25) was 13.3 months vs. 5.3 months (HR 0.39, 95% CI 0.15-0.99). BM+ patients who started on 40 mg had similar PFS to patients with no BM (13.3 months vs. 15.0 months; HR 0.79, 95% CI 0.34-1.80). Conclusion: In patients with advanced EGFRm+ NSCLC with BM+, initiating patients on afatinib 40 mg OD was associated with improved PFS compared to 30 mg OD, underscoring the potential importance of dose intensity in control of CNS disease. | |
dc.language.iso | en | |
dc.publisher | BMC | |
dc.source | Elements | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Oncology | |
dc.subject | EGFR mutation NSCLC | |
dc.subject | Metastatic | |
dc.subject | Afatinib | |
dc.subject | Brain metastases | |
dc.subject | Dose | |
dc.subject | CELL LUNG-CANCER | |
dc.subject | RECEPTOR GENE-MUTATIONS | |
dc.subject | INTERNATIONAL-ASSOCIATION | |
dc.subject | EFFICACY | |
dc.subject | ADENOCARCINOMA | |
dc.subject | GEFITINIB | |
dc.subject | ERLOTINIB | |
dc.subject | SAFETY | |
dc.subject | COMMON | |
dc.type | Article | |
dc.date.updated | 2022-04-07T02:40:13Z | |
dc.contributor.department | DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) | |
dc.contributor.department | DUKE-NUS MEDICAL SCHOOL | |
dc.description.doi | 10.1186/s12885-018-5110-2 | |
dc.description.sourcetitle | BMC CANCER | |
dc.description.volume | 18 | |
dc.description.issue | 1 | |
dc.published.state | Published | |
Appears in Collections: | Staff Publications Elements |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.pdf | 806.03 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.